TPOXX® Antiviral Treatment (Tecovirimat)

Concepts

• antivirals
• monkeypox
• antiviral treatment
• small supply of tpoxx
• drug tecovirimat
• treatment of severe cases of monkeypox
• tecovirimat
• tpoxx
• publication of the price
• ongoing negotiations

Location

Description

The monkeypox virus belongs to a family of viruses called orthopox viruses and the drug Tecovirimat is an antiviral designed specifically to treat viral infections of this kind. In the current outbreak, Tecovirimat has been successfully used to treat patients with the most severe presentations of monkeypox virus infection. This contract is for a small supply of TPOXX® Antiviral Treatment (Tecovirimat) for the treatment of severe cases of Monkeypox in the UK. Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate the price per dose. Publication of this information would therefore: (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors; and (iii) impact fair competition between vendors.

Award Detail

CPV Codes

• 33651400 - Antivirals for systemic use

Other Information

MMT - UKDHSC TPOXX Conditions of Contract 27072022 _Redacted 03112022 MMT - UKDHSC TPOXX Conditions of Contract 27072022 _Redacted 03112022.pdf